

Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong

Shing Fung Lee,¹ Miguel Angel Luque-Fernandez,²⁻⁴ Yu Hui Chen,⁵ Paul J. Catalano,^{5,6} Chi Leung Chiang,⁷ Eric Yuk-Fai Wan,^{8,9} Ian Chi-Kei Wong,^{8,10} Ming Hui Chen,^{11,12,*} and Andrea K. Ng^{13,*}

¹Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hong Kong; ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA; ³Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; ⁴Department of Non-Communicable Disease and Cancer Epidemiology, Instituto de Investigacion Biosanitaria de Granada, University of Granada, Granada, Spain; ⁵Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; ⁶Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA; ⁷Department of Clinical Oncology, ⁸Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, and ⁹Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong; ¹⁰Centre for Medicines Optimisation Research and Education, Research Department of Policy and Practice, University College London School of Pharmacy, London, United Kingdom; ¹¹Department of Cardiology, ¹²Division of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital, and ¹³Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Key Points

- Our study had the most updated and largest cohort to assess doxorubicin-related cardiotoxicity among patients with DLBCL in Asia.
- A >500 mg absolute dose of doxorubicin, together with hypertension and history of aspirin use confer a particularly high risk of CVD incidence.

Evidence regarding the dose-related impact of doxorubicin on subsequent cardiovascular diseases (CVDs) in Asian patients with diffuse large B-cell lymphoma (DLBCL) without preexisting CVDs is lacking. From a territory-wide electronic database in Hong Kong, we identified adults who were diagnosed with DLBCL and treated with chemotherapy between 2000 and 2018. We evaluated the patients for incident CVDs (including ischemic heart disease, heart failure, and cardiomyopathy). We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure by using flexible parametric competing risk analysis and adjusting for demographics, comorbidities, therapeutic exposure, cardiovascular risk factors, and lifestyle factors. Controls were age- and sex-matched to DLBCL patients. We analyzed 2600 patients and 13 000 controls. The adjusted cause-specific hazard ratio (HR) for CVD in patients treated with >500 mg doxorubicin compared with non-doxorubicin regimens was 2.65 (95% confidence interval [CI], 1.23-5.74; $P = .013$). The 5-, 10-, and 15-year csCIs were 8.2%, 11.3%, and 12.8% in patients vs 3.1%, 4.4%, and 5.2% in controls, respectively. Hypertension (HR, 6.20; 95% CI, 0.79-48.44; $P = .082$) and use of aspirin/angiotensin-converting enzyme inhibitor/beta-blocker at baseline (HR, 2.13-4.63; $P < .001$ to $.002$) might confer a higher risk of subsequent CVDs. In this Hong Kong population-based study, doxorubicin exposure (absolute dose >500 mg), together with hypertension or baseline use of medication for cardiovascular risk factors, was found to be associated with an increase in csCIs of CVDs. Tailoring therapeutic strategies to underlying CVD risk factors and risk-adapted monitoring and follow-up of susceptible DLBCL patients are advisable.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma globally, constituting 25% to 40% of all cases in different geographic regions.¹⁻⁴ The median age at diagnosis is ~70 years.² Effective modern therapeutic strategies have resulted in a 5-year survival exceeding 60%

Submitted 22 June 2020; accepted 9 September 2020; published online 21 October 2020. DOI 10.1182/bloodadvances.2020002737.

*M.H.C. and A.K.N. are joint senior authors.

For original data, please contact Shing Fung Lee at leesfm@ha.org.hk.

The full-text version of this article contains a data supplement.

© 2020 by The American Society of Hematology

according to US population-based data.¹ However, the therapeutic exposures responsible for long-term survival are also implicated in long-term sequelae among survivors. The mainstay of therapeutic regimens for the treatment of patients with DLBCL includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy (RT).⁵ This anthracycline-based chemotherapy regimen can increase the risk of cardiovascular sequelae; exposure to chest RT and preexisting cardiovascular risk factors may also further enhance the risk.⁶⁻¹⁹

However, to our knowledge, anthracycline-related cardiotoxicity has not been studied in an Asian population diagnosed with DLBCL. It has been well documented that the prevalence and management of major cardiovascular risk factors can vary markedly worldwide.²⁰ There are also significant differences in health habits and environmental exposures among Asian populations compared with those in the Western world, which may influence the susceptibility of Western populations to treatment-related cardiotoxicity.²¹⁻²³ An improved understanding of the interacting effects of preexisting comorbidities and lifestyle factors on the relationship between DLBCL therapy and cardiovascular diseases (CVDs) can guide upfront treatment decisions as well as long-term cardiac risk-based survivorship care tailored for this understudied population.

We aimed to determine the association between therapeutic exposure (doxorubicin and RT) and new-onset CVD among DLBCL survivors by analyzing population-based data, including information on major cardiovascular risk factors, comorbidities, and lifestyle factors in a population of DLBCL survivors and controls without cancer in Hong Kong.

Materials and methods

Data sources

We retrieved data from the Clinical Data Analysis and Reporting System (CDARS), an electronic medical database operated by the Hong Kong Hospital Authority. The CDARS was established in 1995 for audit and research purposes. The Hospital Authority is the only public health care provider, and it covers ~90% of all secondary and tertiary care in Hong Kong, which has a population of nearly 7.5 million.^{24,25} Data on patient demographics, diagnoses, hospitalizations, treatments, laboratory results, and causes, times, and dates of death, are recorded in CDARS. In routine practice in the Hong Kong Hospital Authority, clinicians in clinical and hospital settings provide International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for each episode of attendance.^{26,27} In a previous study, these codes revealed a high coding accuracy in diagnosing myocardial infarction and stroke with positive predictive values of 85.4% (95% confidence interval [CI] 78.8%-90.6%) and 91.1% (95% CI, 83.2%-96.1%), respectively.²⁸ Another study also demonstrated the reliability of the administrative database of the Hong Kong Hospital Authority to capture demographics and use of antidiabetic drugs with an almost perfect level of data completeness regarding demographics (100%) and drug prescription (99.98%).²⁷ For other diagnoses, previous studies have also demonstrated high coding accuracy, with positive and negative predictive values exceeding 90%.^{29,30} Patient confidentiality is protected by unique anonymous identifiers that are linked to all data contained in the CDARS to facilitate data retrieval. Various high-quality population-based studies on CVDs, cancers, and medications have been published

based on data retrieved from the CDARS.^{28,31,32} The study protocol was approved by the Research Ethics Committee of the New Territories West Cluster, Hong Kong Hospital Authority (reference no: NTWC/REC/19085).

Case definitions and outcome ascertainment


We used data from the CDARS to identify individuals histologically diagnosed with DLBCL between 31 December 2018 and 1 January 2000. Figure 1 shows the study criteria and the final number of patients who constituted the study cohort.³³ The composite primary outcome was incident CVD after DLBCL diagnosis, including ischemic heart disease, heart failure, and cardiomyopathy clinically diagnosed during inpatient hospital visits or as the cause of death after lymphoma diagnosis (ICD-9 codes are provided in supplemental Table 1). Patients were excluded if they had unknown demographic data or were younger than age 18 years, if they developed CVD before DLBCL diagnosis, and if they had not received chemotherapy for the DLBCL (supplemental Table 2). The follow-up times for CVD continued until the first diagnosis of a CVD event, non-cardiac death, or censor date, whichever was earlier. We censored patients who remained alive and had not developed CVD by the end of follow-up on 30 September 2019. Follow-up started after the date of histologic lymphoma diagnosis and ended 15 years after diagnosis. We counted the events only if the diagnosis of CVD occurred beyond a landmark period of 9 months after lymphoma diagnosis because most patients have completed the first-line treatment by that time. Because of the heavily subsidized health care system in Hong Kong, patients with chronic diseases and serious complications (eg, myocardial infarction) are treated mostly in the Hong Kong Hospital Authority public health care system.³⁴ Therefore, the Hong Kong Hospital Authority data should have captured nearly all hospital-managed CVD outcomes with dates available.

Preexisting cardiovascular risk factors, comorbidities, and other variables

The cardiovascular risk factors included hypertension, dyslipidemia, diabetes, chronic obstructive pulmonary disease (COPD), alcohol-related diseases, atrial fibrillation, and history of depression (supplemental Table 3).^{35,36} Diabetes, hypertension, and dyslipidemia were determined by using a combination of ICD-9 codes and the prescriptions for medications for these conditions (supplemental Table 3). We used approaches similar to those adopted by Poulsen et al³⁷ to determine COPD, smoking status, and alcohol-related diseases because these data were not directly available in the CDARS. COPD and smoking status were captured by ICD-9 codes 491, 492, 496, and V15.82.³⁷ We identified alcohol-related diseases, which include hepatic and gastrointestinal diseases and neurologic and psychiatric diseases (ICD-9 codes 291, 303, 305.0, 571, 980).³⁷

We included sex and age at diagnosis. Comorbid conditions before the lymphoma diagnosis were measured using the Royal College of Surgeons (RCS) adaptation of the Charlson Comorbidity Index (CCI).³⁸ Overlapping cardiovascular risk factors were removed from the overall RCS score. The remaining comorbidities in the CCI (peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, liver disease, hemiplegia/paraplegia, renal disease, and AIDS/HIV infection) were combined into the score and examined as such. We extracted

Figure 1. Flowchart outlining the inclusion and exclusion criteria (N = 2600), Hong Kong, 2000-2018.



information regarding the need for medical fee waiver as a surrogate for lower socioeconomic status.

Normal comparison group

The normal comparison group of people selected from a non-cancer random sample without replacement from primary care clinics were sex- and age-matched (within 3 years) to DLBCL patients in a 5:1 ratio. The normal comparison group had no previous diagnosis of cancer or CVD. Both the DLBCL and normal comparison cohort have been retrieved from all 18 districts of Hong Kong.

Treatment information

The treatment data included chemotherapy regimens (doxorubicin- vs non-doxorubicin-based), rituximab, and the use of RT. The absolute prescribed doses of doxorubicin were determined from pharmacy records. The selected patients did not receive anthracyclines other than doxorubicin. Patients exposed to doxorubicin were grouped according to the absolute cumulative doses (≤ 500 or > 500 mg, ~ 300 mg/m², or 6 cycles of doxorubicin-based treatment, assuming an average body surface area of 1.67 m², which is a reasonable number based on local data).³⁹

Statistical analysis

Descriptive statistics for demographics, follow-up duration, and prevalence of characteristics were generated for the DLBCL survivors and normal comparison group. Continuous variables were presented as medians with interquartile ranges and were compared using rank-sum tests, whereas categorical variables were presented as percentages and compared using χ^2 tests. To investigate potential confounding by indication, we cross-tabulated preexisting

cardiovascular risk factors with receipt of doxorubicin and tested for associations using χ^2 tests.

With the hypothesis that doxorubicin exposure drives the differences in CVD outcomes between groups, we used a cause-specific hazard framework to deal with the competing risks of non-cardiac mortality and to derive cause-specific hazard ratios (HRs).^{40,41} We evaluated the cause-specific cumulative incidence (csCI) of CVD with levels of doxorubicin exposure using flexible parametric competing risk analysis.⁴²⁻⁴⁵ We considered non-cardiac mortality as a competing risk when comparing csCIs between lymphoma survivors and the normal comparison group.^{42,43,46,47} The csCI of CVD was derived after adjusting for age, sex, race, year of diagnosis, need for medical fee waiver, cumulative dose of doxorubicin, receipt of RT, rituximab administration, preexisting cardiovascular risk factors (COPD or smoking, alcohol-related diseases, atrial fibrillation, hypertension, hyperlipidemia, dyslipidemia, diabetes mellitus, and depression), use of aspirin, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors (supplemental Table 3), and RCS comorbidity score. The csCIs of CVD for DLBCL patients and the normal comparison group are illustrated by using cumulative incidence plots. In secondary analyses, we included the csCI plots of each CVD end point (ie, heart failure, cardiomyopathy, and ischemic heart disease) for DLBCL patients and the normal comparison group. We computed the ratios of predicted cumulative incidence of lymphoma death and CVD among DLBCL patients at 5, 10, and 15 years and computed their respective 95% confidence intervals (CIs) by bootstrapping. We performed a sensitivity analysis to test whether the results were robust with respect to the absence of landmark period and doxorubicin dose cutoff. We used Stata v.16.1 (StataCorp, College Station, TX), including the command `stpm2` (version 1.7.4) to perform the

statistical analyses and fit the flexible parametric survival models.^{48,49}

Results

The characteristics of the DLBCL cohort (N = 2600) and the normal comparison group (N = 13 000) are detailed in Table 1. The median age at diagnosis for the DLBCL cohort was 63 years (interquartile range [IQR], 53-73 years) and 56.0% were male. As of September 30, 2019, the median follow-up time from the index date for the entire lymphoma survivor cohort was 6.8 years (IQR, 3.6-10.5 years), providing 13 352 person-years of follow-up. Beyond 9 months from diagnosis, 118 (4.5%) of the DLBCL survivors developed CVDs, with a median interval to CVD of 3.9 years (IQR, 1.8-6.0 years). Among DLBCL survivors, most deaths were a result of lymphoma (53.8%), followed by pulmonary disorders (17.0%), and infections (3.8%). Prescription of doxorubicin was associated with age, cardiovascular risk factors, and social factors such that patients who were older (odds ratio [OR] per 1-year increase in age, 0.96; 95% CI, 0.96-0.97; $P < .001$), had diabetes (OR, 0.70; 95% CI, 0.57-0.86; $P < .001$), hypertension (OR, 0.73; 95% CI, 0.61-0.88; $P < .001$), dyslipidemia or hyperlipidemia (OR, 0.69; 95% CI, 0.56-0.85; $P < .001$), ACE inhibitor use (OR, 0.74; 95% CI, 0.61-0.92; $P = .005$), or received medical fee waiver (OR, 0.61; 95% CI, 0.44-0.86; $P = .004$) were less commonly administered doxorubicin. The median age of patients who received doxorubicin vs those who did not was 57 vs 66 years, respectively (rank-sum test $P < .001$). Supplemental Table 4 provides the characteristics of patients who received different regimens.

Those in the normal comparison group compared with DLBCL survivors were significantly more likely to have hypertension (80.0% vs 69.1%; $P < .001$), diabetes (36.2% vs 23.0%; $P < .001$), dyslipidemia or hyperlipidemia (48.8% vs 22.5%; $P < .001$), anxiety or depressive disorder (26.4% vs 16.8%; $P < .001$), be smokers (43.6% vs 24.8%; $P < .001$), or require a medical fee waiver (24.5% vs 7.7%; $P < .001$) (Table 1).

After multivariable adjustment (Table 2), patients treated with >500 mg absolute dose of doxorubicin had an approximately threefold increased risk of CVD compared with patients treated with regimens that did not contain doxorubicin (adjusted cause-specific HR, 2.55; 95% CI, 1.18-5.53; $P = .017$). The cumulative incidence curves reflected the results of the regression analysis. The patients who had received >500 mg absolute dose of doxorubicin had 5-, 10- and 15-year csCIs of CVD of 8.0%, 11.1%, and 12.5% respectively; the corresponding incidence rates for patients treated with \leq 500 mg were 4.2%, 6.0%, and 7.0%, respectively; and those for patients treated with non-doxorubicin regimens, the corresponding incidence rates were 3.8%, 5.6%, and 6.5%, respectively. The incidence estimates for the normal comparison group were 3.1%, 4.4%, and 5.2%, respectively (Figure 2).

Aspirin use (HR, 4.63; 95% CI, 2.54-8.43; $P < .001$), ACE inhibitor use (HR, 2.13; 95% CI, 1.32-3.42; $P = .002$), beta blocker use (HR, 2.18; 95% CI, 2.54-8.43; $P < .001$), and hypertension (HR, 6.21; 95% CI, 0.80-48.43; $P = .081$) at baseline were also associated with subsequent CVDs. Patients with preexisting hypertension who used aspirin and who received >500 mg of doxorubicin had 5-, 10-, and 15-year csCIs of CVD of 12.1%, 18.4%, and 21.1%, respectively (supplemental Figure 1).

The csCI plots of CVD end points (ie, heart failure/cardiomyopathy and ischemic heart disease) for DLBCL patients and the normal comparison group showed association between doxorubicin and outcomes similar to those in the main analysis (Figure 3A-B). The ratios of predicted cumulative incidence of lymphoma death and CVD among DLBCL patients at 5, 10, and 15 years were 4.99 (95% CI, 4.95-5.03; $P < .001$), 3.48 (95% CI, 3.47-3.48; $P < .001$), and 3.08 (95% CI, 3.07-3.08; $P < .001$), respectively (Figure 4). Repeated analyses with and without landmark periods produced largely consistent results (Table 2; supplemental Figure 2). Analysis of different cutoff doses of doxorubicin did not change our main findings. We found that 42 lymphoma patients and 149 people from the normal comparison group had one of the major autoimmune diseases (supplemental Table 3). A χ^2 test between aspirin and major autoimmune diseases showed weak evidence of association ($P = .635$).

Discussion

Our analysis of a contemporary cohort of 2600 patients diagnosed with DLBCL without previous heart disease and 13 000 age- and sex-matched normal comparison group (all derived from a Hong Kong population electronic medical records database) revealed an increased risk of cancer survivors developing CVDs, despite their lower prevalence of underlying CVD risk factors compared with the normal comparison group. Among the patients with DLBCL, the receipt of a cumulative absolute doxorubicin dose of 500 mg (\sim 300 mg/m²) was associated with a threefold increased risk of CVD compared with that for treatment with non-doxorubicin regimens. We found that preexisting hypertension and aspirin use were associated with higher subsequent risk of CVD. We hypothesize that history of aspirin on the medication list is likely a surrogate for high cardiovascular risk. This is a secondary finding supplementary to the main results largely because of data sparsity and multiple comparisons in end points. Aspirin could be prescribed for other medical conditions such as autoimmune diseases. However, our sensitivity analysis has revealed weak association between aspirin use and autoimmune diseases. The ratios of lymphoma death and CVD among DLBCL patients decreased with time, implying that CVD might be a larger health burden than lymphoma itself as follow-up time increases.

The association between doxorubicin and cardiac risks is well-established in the Western world. In patients with aggressive non-Hodgkin lymphoma, a Surveillance, Epidemiology, and End Results (SEER)-Medicare study that included 9438 patients with DLBCL showed that doxorubicin, older age, presence of comorbidity, hypertension, diabetes, preexisting atherosclerotic disease, and preexisting heart disease were significantly associated with subsequent risks of congestive heart failure (CHF).¹⁸ A Danish registry study of 2508 non-Hodgkin lymphoma survivors found that cumulative doxorubicin dose (per 100 mg/m²), older age, male sex, prediagnosis CVD risk factors, and prediagnosis of intrinsic heart disease were significantly associated with the risk of CHF.¹⁰ The authors also reported the 5-year risks of CHF by age, sex, preexisting heart disease, and CVD risk factors after a median follow-up time of 2.5 years.¹⁰ Unlike in previous studies, our study excluded patients who did not receive chemotherapy and those with preexisting cardiovascular events, so that the very frail were excluded from our

Table 1. Characteristics of DLBCL survivors (N = 2600) and matched general population comparison group (N = 13 000) in Hong Kong, 2000-2018

| Characteristic | All lymphoma patients (N = 2600) | Normal comparison group (n = 13 000) | P | Lymphoma patients categorized by CVD status (N = 2600) | | P |
|--|-------------------------------------|---|-------|---|-------------------|-------|
| | | | | CVD (n = 175) | No CVD (n = 2425) | |
| Patient factors | | | | | | |
| Median age at lymphoma diagnosis (IQR), y | 63 (53-73) | 63 (54-72) | —* | 70 (62-79) | 62 (52-72) | <.001 |
| Sex | | | —* | | | .875 |
| Male | 1456 (56.0) | 7 280 (56.0) | | 99 (56.6) | 1357 (56.0) | |
| Female | 1144 (44.0) | 5 720 (44.0) | | 76 (43.4) | 1068 (44.0) | |
| Race/ethnicity | | | .001 | | | .068 |
| Chinese | 2484 (95.5) | 12 586 (96.8) | | 172 (98.3) | 2312 (95.3) | |
| Non-Chinese | 116 (4.5) | 414 (3.2) | | 3 (1.7) | 113 (4.7) | |
| RCS comorbidity scores | | | <.001 | | | <.001 |
| 0 | 1710 (65.8) | 8 871 (68.2) | | 69 (39.4) | 1641 (67.7) | |
| 1 | 664 (25.5) | 2 631 (20.2) | | 61 (34.9) | 603 (24.9) | |
| ≥2 | 226 (8.7) | 1 498 (11.5) | | 45 (25.7) | 181 (7.5) | |
| Median follow-up time for alive patients (IQR), y | 6.8 (3.6-10.5) | 7.8 (4.4-10.9) | <.001 | 5.3 (1.9-7.5) | 6.9 (3.6-10.6) | <.001 |
| Year of diagnosis | | | — | | | <.001 |
| 2000-2004 | 398 (15.3) | — | | 37 (21.1) | 361 (14.9) | |
| 2005-2009 | 697 (26.8) | — | | 68 (38.9) | 629 (25.9) | |
| 2010-2014 | 870 (33.5) | — | | 51 (29.1) | 819 (33.8) | |
| 2015-2018 | 635 (24.4) | — | | 19 (10.9) | 616 (25.4) | |
| Fee waiver recipients (surrogate for lower socioeconomic status) | 200 (7.7) | 3 186 (24.5) | <.001 | 22 (12.6) | 178 (7.3) | .012 |
| COPD or smoker | 645 (24.8) | 5 662 (43.6) | <.001 | 72 (41.1) | 573 (23.6) | <.001 |
| Alcohol-related diseases | 18 (0.7) | 98 (0.8) | .739 | 0 (0.0) | 18 (0.7) | .253 |
| Diabetes mellitus | 598 (23.0) | 4 708 (36.2) | <.001 | 71 (40.6) | 527 (21.7) | <.001 |
| Hypertension | 1797 (69.1) | 10 393 (80.0) | <.001 | 173 (98.9) | 1624 (67.0) | <.001 |
| Dyslipidemia/hyperlipidemia | 586 (22.5) | 6 349 (48.8) | <.001 | 84 (48.0) | 502 (20.7) | <.001 |
| Anxiety or depressive disorders | 436 (16.8) | 3 435 (26.4) | <.001 | 37 (21.1) | 399 (16.4) | .109 |
| Atrial fibrillation | 31 (1.2) | 514 (4.0) | <.001 | 7 (4.0) | 24 (1.0) | <.001 |
| ACE inhibitor use | 574 (22.1) | 5 269 (40.5) | <.001 | 102 (58.3) | 472 (19.5) | <.001 |
| Beta blocker use | 792 (30.5) | 5 436 (41.8) | <.001 | 119 (68.0) | 673 (27.8) | <.001 |
| Aspirin use | 602 (23.2) | 5 266 (40.5) | <.001 | 131 (74.9) | 471 (19.4) | <.001 |
| Treatment factors | | | | | | |
| Chemotherapy | | — | — | | | .761 |
| Regimens containing doxorubicin | | | | | | |
| >500 mg | 166 (6.4) | — | | 13 (7.4) | 153 (6.3) | |
| ≤500 mg | 699 (26.9) | — | | 44 (25.2) | 655 (27.0) | |
| Non-doxorubicin regimens | 1735 (66.7) | — | | 118 (67.4) | 1617 (66.7) | |
| RT | 308 (11.9) | — | — | 25 (14.3) | 283 (11.7) | .301 |
| Rituximab | 1980 (76.2) | — | — | 126 (72.0) | 49 (28.0) | .182 |

All data are no. (%) unless otherwise indicated.

*People in the normal comparison group were sex- and age-matched to lymphoma patients.

analysis. Despite our more stringent inclusion criteria, we still detected significantly increased CVD risks among DLBCL survivors; at a median follow-up of 6.8 years, the 10-year estimated csCI of CVD was 18.4% in patients with cardiac risk factors who had received >500 mg absolute dose of doxorubicin.

In our selected study cohort, hypertension was the most prevalent preexisting cardiac risk factor, and its presence was associated with an estimated sixfold increased risk of subsequent CVD, although the wide confidence interval reflects the limited power, and the association could have been weakened because we included in the model ACE inhibitors and beta blockers, which are commonly used

Table 2. Cause-specific HRs for new-onset cardiovascular disease among patients with DLBCL from unadjusted and adjusted analyses including with and without 9-mo landmark period (N = 2600) in Hong Kong, 2000-2018

| Characteristic* | No landmark period | | | | 9-mo landmark period | | | |
|--|-------------------------|-------|-----------------------|-------|-------------------------|-------|-----------------------|-------|
| | Unadjusted HR (95% CI)† | P | Adjusted HR (95% CI)† | P | Unadjusted HR (95% CI)† | P | Adjusted HR (95% CI)† | P |
| Treatment factors | | | | | | | | |
| Chemotherapy | | | | | | | | |
| Doxorubicin ≤500 mg vs non-doxorubicin regimen | 0.86 (0.61-1.22) | .405 | 0.98 (0.66-1.44) | .902 | 0.89 (0.59-1.36) | .599 | 1.21 (0.75-1.94) | .437 |
| Doxorubicin >500 mg vs non-doxorubicin regimen | 1.03 (0.58-1.82) | .927 | 1.43 (0.76-2.71) | .270 | 1.16 (0.60-2.25) | .651 | 2.55 (1.18-5.53) | .017 |
| Receipt of RT | 1.24 (0.80-1.90) | .333 | 0.81 (0.47-1.41) | .464 | 1.07 (0.61-1.87) | .805 | 0.59 (0.30-1.15) | .120 |
| Rituximab | 0.82 (0.58-1.14) | .244 | 0.60 (0.39-0.93) | .023 | 0.81 (0.54-1.21) | .302 | 0.68 (0.41-1.15) | .154 |
| Patient factors | | | | | | | | |
| Age at lymphoma diagnosis (per 1-y increase) | 1.05 (1.04-1.06) | <.001 | 1.01 (1.00-1.03) | .138 | 1.05 (1.04-1.06) | <.001 | 1.01 (0.99-1.03) | .409 |
| Sex (male vs female) | 1.15 (0.85-1.56) | .350 | 1.08 (0.76-1.54) | .645 | 1.12 (0.78-1.61) | .536 | 1.01 (0.66-1.55) | .966 |
| RCS comorbidity score‡ | | | | | | | | |
| 1 vs 0 | 2.49 (1.76-3.52) | <.001 | 1.16 (0.77-1.76) | .473 | 2.41 (1.57-3.70) | <.001 | 1.11 (0.67-1.83) | .687 |
| 2 vs 0 | 5.24 (3.59-7.66) | <.001 | 1.01 (0.59-1.72) | .967 | 5.86 (3.75-9.17) | <.001 | 0.99 (0.53-1.94) | .974 |
| Year of diagnosis | | | | | | | | |
| 2005-2009 vs 2000-2004 | 1.16 (0.77-1.75) | .471 | 1.16 (0.72-1.89) | .540 | 1.02 (0.64-1.62) | .921 | 1.03 (0.60-1.76) | .917 |
| 2010-2014 vs 2000-2004 | 0.83 (0.53-1.28) | .396 | 0.92 (0.52-1.64) | .776 | 0.76 (0.45-1.26) | .281 | 0.76 (0.40-1.44) | .400 |
| 2015-2018 vs 2000-2004 | 0.70 (0.39-1.24) | .221 | 1.08 (0.54-2.16) | .823 | 0.20 (0.06-0.67) | .009 | 0.28 (0.07-1.10) | .068 |
| Fee waiver recipients (surrogate for lower socioeconomic status) | 1.74 (1.11-2.72) | .015 | 1.12 (0.66-1.90) | .661 | 1.84 (1.09-3.13) | .023 | 1.14 (0.62-2.11) | .675 |
| COPD or smoker | 1.94 (1.43-2.63) | <.001 | 1.27 (0.89-1.81) | .192 | 2.12 (1.48-3.05) | <.001 | 1.32 (0.86-2.02) | .203 |
| Diabetes mellitus | 2.65 (1.96-3.59) | <.001 | 1.16 (0.79-1.72) | .442 | 2.36 (1.62-3.43) | <.001 | 0.85 (0.53-1.36) | .495 |
| Hypertension | 46.70 (11.58-188.25) | <.001 | 6.62 (1.45-30.10) | .014 | 68.14 (9.52-487.82) | <.001 | 6.21 (0.80-48.43) | .081 |
| Dyslipidemia/hyperlipidemia | 2.86 (2.12-3.86) | <.001 | 1.01 (0.71-1.44) | .953 | 3.28 (2.29-4.71) | <.001 | 1.18 (0.77-1.82) | .444 |
| Anxiety or depressive disorders | 1.38 (0.96-1.98) | .085 | 0.98 (0.66-1.47) | .941 | 1.36 (0.88-2.12) | .167 | 0.90 (0.56-1.43) | .650 |
| ACE inhibitor use | 5.24 (3.87-7.09) | <.001 | 1.95 (1.30-2.93) | .001 | 5.52 (3.82-7.97) | <.001 | 2.13 (1.32-3.42) | .002 |
| Beta blocker use | 5.14 (3.74-7.07) | <.001 | 1.66 (1.12-2.44) | .011 | 7.07 (4.69-10.65) | <.001 | 2.18 (1.32-3.60) | .002 |
| Aspirin use | 9.71 (6.90-13.67) | <.001 | 4.35 (2.80-6.76) | <.001 | 11.60 (7.51-17.93) | <.001 | 4.63 (2.54-8.43) | <.001 |

*Race, alcohol-related diseases, and atrial fibrillation were not adjusted in the model because most of the patients were Hong Kong Chinese and too few patients had alcohol-related diseases and atrial fibrillation.


†Cause-specific HRs by competing risk analyses.

‡Included peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatic disease, liver disease, hemiplegia/paraplegia, renal disease, AIDS/HIV infection.

for hypertension. Anthracyclines can induce abnormal cell signaling and cytotoxic molecules that are in common with those produced by hypertension.^{50,51} The resultant oxidative stress and inflammatory processes induce damage to the cardiovascular system.⁵¹ Our finding is consistent with the pathophysiology that hypertension can exacerbate the cardiotoxic effects of doxorubicin.⁵⁰ The most prevalent CVD risk factor in Asia is hypertension.⁵² Therefore, Asian countries are faced with the challenge of large numbers of hypertensive patients who also have very low awareness of this silent risk factor and a history of low rates of blood pressure control.⁵²⁻⁵⁴ Our findings underscore the importance of tailoring DLBCL treatment decisions on the basis of population-specific data and the prevalence of preexisting cardiac risk factors, including a history of hypertension and/or other cardiovascular risk factors. This suggests that aggressive control of blood pressure and close follow-up of DLBCL survivors after exposure to doxorubicin may be more clinically important.

For posttreatment cardiac surveillance, the American Society of Clinical Oncology Clinical Practice Guidelines recommend that an echocardiogram be performed between 6 and 12 months after completion of cancer-directed therapy in asymptomatic patients at increased risk of cardiac dysfunction.⁵⁵ The European Society of Medical Oncology recommends consideration of left ventricular ejection fraction assessment at 6 to 12 months and possibly 2 years posttreatment, as well as periodic reassessment thereafter in asymptomatic patients with normal baseline ejection fraction after anthracycline-based chemotherapy.⁵⁶ Cardiology authorities have also published guidelines on monitoring after anthracyclines. They recommended a more frequent assessment of cardiac function^{57,58}; document baseline left ventricular ejection fraction, repeat measurement after doxorubicin dose reaches 240 mg/m², and repeat measurement for each additional 50 mg/m², then reassess 6 months after completing therapy. Our finding that most CVDs

Figure 2. csCIs of cardiovascular diseases for DLBCL survivors, Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated by levels of exposure to doxorubicin (N = 2600) and in the normal comparison group (N = 13 000) with non-cardiac death as a competing risk.



developed within the first few years after treatment (median, ~4 years) supports these recommendations of cardiac evaluation early posttreatment. Implementation of such stringent risk stratifications and early frequent cardiac assessment could have potentially allowed earlier detection of some of the cardiotoxicities and potentially the ability to prevent CVD events in the future. We propose that the follow-up of patients in this period by oncologists

and primary care physicians should focus not only on disease relapse but also on the evaluation for and prompt treatment of cardiac risk factors, with cardiac screening of asymptomatic patients.

Our study has several limitations. The data were subject to confounding by indication in that participants with subclinical




Figure 3. csCIs of ischemic heart disease, heart failure, and cardiomyopathy for DLBCL survivors, Hong Kong, 2000-2018. csCIs of ischemic heart disease (A) and heart failure and cardiomyopathy (B) were estimated by levels of exposure to doxorubicin (N = 2600) and in normal comparison group (N = 13 000) with non-cardiac death as competing risk.




Figure 4. csCIs of cardiovascular diseases in comparison with lymphoma death among DLBCL survivors, Hong Kong, 2000-2018. csCIs of cardiovascular diseases were estimated (N = 2600) with death as a result of lymphoma as a competing risk.

medical conditions not measurable by our methodology may have been less likely to receive doxorubicin-containing regimens. In our determination of outcome events, we restricted the primary outcome to CVD diagnosed at a hospital or death to conservatively capture the symptomatic and most severe cases.⁵⁹ This suggests that our study might underestimate the true incidence of cardiotoxicity by not capturing milder forms of CVD events. However, this can avoid misclassification as a result of coding errors and uncertainty in the diagnosis of milder CVD events. Previous studies have demonstrated high sensitivity and specificity in diagnosis and medication code retrieval from CDARS.^{27,28} It is likely that we would have captured the majority of the CVDs diagnosed at the hospital and death, given our public health care system.³⁴ In addition, the registry database lacks detailed information on lymphoma and its treatment, including the stage at diagnosis, body surface area, and RT site and dose. Similar to other studies of electronic medical record databases, our study also lacked data on important lifestyle factors such as physical activity level and diet, which are known to have an impact on the onset of CVD. Although these limitations tend to bias our estimates toward the null, we still detected important associations between doxorubicin and cardiovascular risk factors and risk of CVD. Despite these limitations, our study has several strengths. We analyzed a reasonably large and homogeneous cohort in Hong Kong. Some studies used claims data or the number of cycles as surrogate estimates for chemotherapy dose.^{10,18,60} However, chemotherapy dose reductions are common, especially in elderly patients older than age 75 years.⁶⁰⁻⁶³ In a study of US veterans, only 14% of patients age 80 years or older who received doxorubicin completed treatment at $\geq 85\%$ dose intensity.⁶² We described the magnitude of CVD risks segregated by actual doxorubicin dose levels among patients with DLBCL who received chemotherapy as part of anticancer treatment. Hequet et al¹¹ reported that subclinical cardiomyopathy was more common than clinically overt cardiomyopathy. Although we used diagnosis codes to identify outcome events, we avoided overdiagnosis by using only inpatient codes that generally indicated greater severity, thereby reducing the risk of misclassification.

This study demonstrated for the first time that doxorubicin contributed to excess cardiotoxicity in a dose-related manner in a Hong Kong population of patients with DLBCL without preexisting CVD. In addition, hypertension, an often under-recognized and undertreated condition rampant among Asian patients,⁵² was associated with an increased trend of therapy-related CVD. We also found that many incident CVDs in our study occurred soon after lymphoma treatment. Together, these findings highlight the importance of pretreatment screening for CVD risk factors, careful balancing of the risks and benefits of treatment decisions, rigorous monitoring of cardiac function, and early cardiac screening and intervention to minimize the risk of CVD during and after lymphoma treatment and throughout cancer survivorship.

Acknowledgment

The authors thank K.F. Tsang (Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong) for clerical support and data retrieval.

This work was supported by a grant from National Institutes of Health (NIH), Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences) (UL1TR002541) and by Harvard University and its affiliated academic health care centers. M.A.L.-F. was supported by a Spanish National Health Institute Carlos III Miguel Servet-I Investigator grant/award (CP17/00206-EU-FEDER). M.H.C. was supported by a grant from the NIH, National Cancer Institute (R01 CA196854).

The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authorship

Contribution: S.F.L. and M.A.L.-F. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; S.F.L., A.K.N., and M.H.C. conceived the idea for and design of the study; S.F.L. collected and assembled

the data; S.F.L., M.A.L.-F., Y.H.C., P.J.C., C.L.C., E.Y.-F.W., I.C.-K.W., M.H.C., and A.K.N. analyzed and interpreted the data; and all authors helped prepare the manuscript and gave final approval of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: S.F.L., 0000-0003-4696-9434; M.A.L.-F., 0000-0001-6683-5164; Y.H.C., 0000-0003-4292-698X; P.J.C.,

0000-0002-1105-8852; E.Y.-F.W., 0000-0002-6275-1147; I.C.-K.W., 0000-0001-8242-0014; A.K.N., 0000-0001-8428-7421.

Correspondence: Andrea K. Ng, Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, ASB1-L2, 75 Francis St, Boston, MA 02115; e-mail: ang@iroc.harvard.edu; and Ming Hui Chen, Department of Cardiology, 300 Longwood Ave, Boston, MA 02115; e-mail: minghui.chen@cardio.chboston.org.

References

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin*. 2016;66(6):443-459.
2. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. *Pathology*. 2018;50(1):74-87.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
4. Miranda-Filho A, Piñeros M, Znaor A, Marcos-Gragera R, Steliarova-Foucher E, Bray F. Global patterns and trends in the incidence of non-Hodgkin lymphoma. *Cancer Causes Control*. 2019;30(5):489-499.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma (version 3.2020). https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 1 April 2020.
6. Hung OY, Brown JR, Dai T, Easley KA, Flowers CR, Parashar S. Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy. *BMJ Open*. 2015;5:e008350.
7. Carver JR, Shapiro CL, Ng A, et al; ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. *J Clin Oncol*. 2007;25(25):3991-4008.
8. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*. 2016;66(1):7-30.
9. Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. *Blood*. 2006;107(7):2912-2919.
10. Salz T, Zabor EC, de Nully Brown P, et al. Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors. *J Clin Oncol*. 2017;35(34):3837-3843.
11. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. *J Clin Oncol*. 2004;22(10):1864-1871.
12. Smith SK, Zimmerman S, Williams CS, Zebrack BJ. Health status and quality of life among non-Hodgkin lymphoma survivors. *Cancer*. 2009;115(14):3312-3323.
13. Jensen RE, Arora NK, Bellizzi KM, et al. Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. *Cancer*. 2013;119(3):672-680.
14. Smith SK, Mayer DK, Zimmerman S, et al. Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study. *J Clin Oncol*. 2013;31(2):272-279.
15. Tsai HT, Pfeiffer RM, Warren J, Wilson W, Landgren O. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2015;56(3):682-687.
16. Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. *J Clin Oncol*. 2016;34(10):1122-1130.
17. Kenzik KM, Mehta A, Richman JS, Kilgore M, Bhatia S. Congestive heart failure in older adults diagnosed with follicular lymphoma: a population-based study. *Cancer*. 2018;124(21):4221-4230.
18. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. *J Clin Oncol*. 2008;26(19):3159-3165.
19. Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. *Br J Haematol*. 2018;183(5):717-726.
20. Ferrari R, Ford I, Greenlaw N, et al; CLARIFY Registry Investigators. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry. *Eur J Prev Cardiol*. 2015;22(8):1056-1065.
21. Woodward M, Lam TH, Barzi F, et al; Asia Pacific Cohort Studies Collaboration. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. *Int J Epidemiol*. 2005;34(5):1036-1045.
22. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia: a selected review. *Circulation*. 2008;118(25):2702-2709.
23. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. *Nat Rev Cardiol*. 2019;16(4):203-212.

24. Hospital Authority. HA Statistical Report 2018-2019. <https://www3.ha.org.hk/data/HASStatistics/StatisticalReport/2018-2019>. Accessed 1 March 2020.
25. Census and Statistics Department, The Government of the Hong Kong Special Administrative Region. Population, 2020. <https://www.censtatd.gov.hk/hkstat/sub/so20.jsp>. Accessed 8 August 2020.
26. The American Health Information Management Association. Hospital Authority Clinical Vocabulary Table: the Past, the Present, and the Future. <https://library.ahima.org/doc?oid=58669#.X3KFW-17mHs>. Accessed 14 July 2020.
27. Wong MC, Jiang JY, Tang JL, Lam A, Fung H, Mercer SW. Health services research in the public healthcare system in Hong Kong: an analysis of over 1 million antihypertensive prescriptions between 2004-2007 as an example of the potential and pitfalls of using routinely collected electronic patient data. *BMC Health Serv Res*. 2008;8(1):138.
28. Wong AYS, Root A, Douglas IJ, et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. *BMJ*. 2016;352:h6926.
29. Wong OF, Ho PL, Lam SK. Retrospective review of clinical presentations, microbiology, and outcomes of patients with psoas abscess. *Hong Kong Med J*. 2013;19(5):416-423.
30. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. *Gastroenterology*. 2015;149(3):586-595.e3.
31. Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for *Helicobacter pylori*: a population-based study. *Gut*. 2018;67(1):28-35.
32. Lau WC, Chan EW, Cheung CL, et al. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. *JAMA*. 2017;317(11):1151-1158.
33. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
34. Lee CP. Health care system and pharmacy practice in Hong Kong. *Can J Hosp Pharm*. 2018;71(2):140-148.
35. Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation*. 1999;100(13):1481-1492.
36. Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. *Eur Heart J*. 2020;41(17):1687-1696.
37. Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. *Br J Cancer*. 2009;100(9):1503-1507.
38. Brusselaers N, Lagergren J. The Charlson Comorbidity Index in registry-based research. *Methods Inf Med*. 2017;56(5):401-406.
39. Leung SSF, Department of Paediatrics, The Chinese University of Hong Kong, Growth Standard of Southern Chinese. <http://www.cuhk.edu.hk/proj/growthstd/index.htm>. Accessed 1 May 2020.
40. Gichangi A, Vach W. The analysis of competing risks data: a guided tour. *Stat Med*. 2005;132.
41. Pintilie M. *Competing Risks: A Practical Perspective*. Chichester, United Kingdom: Wiley; 2006.
42. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. *Int J Epidemiol*. 2012;41(3):861-870.
43. Kipourou D-K, Charvat H, Rachet B, Belot A. Estimation of the adjusted cause-specific cumulative probability using flexible regression models for the cause-specific hazards. *Stat Med*. 2019;38(20):3896-3910.
44. Lambert P. Standardized cumulative incidence functions. https://pclambert.net/software/standsurv/standardized_cif/. Accessed 5 March 2020.
45. Armitage P, Berry G, Matthews JNS. *Statistical Methods in Medical Research*. 4th ed.. Oxford, United Kingdom: Blackwell Science; 2002.
46. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16(3):1141-1154.
47. Geskus RB. *Data Analysis With Competing Risks and Intermediate States*. London, United Kingdom: CRC Press, Taylor and Francis Group; 2016.
48. StataCorp. *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC; 2019.
49. Royston P. Flexible parametric alternatives to the Cox model: update. *Stata J*. 2004;4(1):98-101.
50. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. *N Engl J Med*. 1998;339(13):900-905.
51. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. *Heart*. 2007;93(8):903-907.
52. Jin C-N, Yu C-M, Sun J-P, et al. The healthcare burden of hypertension in Asia. *Heart Asia*. 2013;5(1):238-243.
53. Wu Y, Huxley R, Li L, et al; China NNHS Steering Committee; China NNHS Working Group. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. *Circulation*. 2008;118(25):2679-2686.
54. Ma WJ, Tang JL, Zhang YH, et al. Hypertension prevalence, awareness, treatment, control, and associated factors in adults in southern China. *Am J Hypertens*. 2012;25(5):590-596.
55. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017;35(8):893-911.
56. Curigliano G, Lenihan D, Fradley M, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020;31(2):171-190.

57. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014;27(9):911-939.
58. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37(36):2768-2801.
59. Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. *Eur J Heart Fail*. 2008;10(7):658-660.
60. Juul MB, Jensen PH, Engberg H, et al. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study. *Eur J Cancer*. 2018;99:86-96.
61. Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. *Leuk Lymphoma*. 2014;55(3):526-532.
62. Carson KR, Riedell P, Lynch R, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. *J Geriatr Oncol*. 2015;6(3):211-218.
63. Gobba S, Moccia AA, Gulden-Sala W, et al. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: a large retrospective study from 4 institutions. *Hematol Oncol*. 2018;36(1):84-92.